menu
    • menu
    [{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"STX-478","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Scorpion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Scorpion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"STX-478","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Scorpion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Scorpion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fulvestrant","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Scorpion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Scorpion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Willett Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Series C Financing","leadProduct":"STX-478","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Scorpion Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Scorpion Therapeutics \/ Willett Advisors","highestDevelopmentStatusID":"14","companyTruncated":"Scorpion Therapeutics \/ Willett Advisors"}]

    Find Clinical Drug Pipeline Developments & Deals for STX-478

    Menu

    STX-478

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Scorpion Therapeutics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Scorpion Therapeutics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STX-478,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Willett Advisors

                            Deal Size : $150.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Scorpion Wins $150M Financing to Advance Precision Oncology Pipeline

                            Details : The Proceeds support further mid-stage clinical development of STX-478, mutant-selective PI3Kα program for treating breast cancer as a monotherapy and in combination with Fulvestrant.

                            Brand Name : STX-478

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 16, 2024

                            Lead Product(s) : STX-478,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Willett Advisors

                            Deal Size : $150.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Scorpion Therapeutics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Scorpion Therapeutics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STX-478,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Scorpion Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of STX-478, Its Mutant-Selecti...

                            Details : STX-478 is a mutant-selective PI3Kα inhibitor with a potentially best-in-class profile, for the treatment of HR+/HER2- breast cancer and other solid tumors.'

                            Brand Name : STX-478

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 02, 2023

                            Lead Product(s) : STX-478,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Scorpion Therapeutics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Scorpion Therapeutics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STX-478

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Scorpion Therapeutics Presents Preclinical Data for Potential Best-in-Class PI3Kα Inhibitor at San Antonio Br...

                            Details : In these studies, STX-478 showed robust anti-tumor activity as both a monotherapy and in combination with standard of care agents in models with kinase or helical domain mutations.

                            Brand Name : STX-478

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 08, 2022

                            Lead Product(s) : STX-478

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Scorpion Therapeutics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Scorpion Therapeutics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STX-478

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Scorpion Therapeutics to Present Preclinical Data for Potential Best-in-Class Mutant-Selective PI3Kα Inhibito...

                            Details : STX-478 is a highly selective, allosteric and CNS-penetrant inhibitor of mutant PI3Kα, designed to improve outcomes in patients harboring tumors with prevalent PI3Kα kinase or helical domain mutations.

                            Brand Name : STX-478

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 21, 2022

                            Lead Product(s) : STX-478

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth